Nikon BioImaging Lab Europe Wins Deshima Award for Newcomer Category


[Amsterdam, 15th December 2025] — Nikon BioImaging Lab Europe (NBIL) is delighted to announce that it has been honoured with the prestigious Deshima Award in the “Newcomer” category. The award recognizes NBIL’s innovative approach, ambitious growth plans, future investments, and the positive impact and added value the company brings to the regional economy.

The Deshima Awards celebrate the enduring trade relationship between Japan and the Netherlands, drawing their name from the historic Japanese island of Deshima, which served as a Dutch trading post from 1641 to 1854. Established in 2007 by the Netherlands Foreign Investment Agency (NFIA) and the Dutch & Japanese Trade Federation (DUJAT), the awards highlight the significance of Japanese investment in the Netherlands and honour companies that contribute to economic development and bilateral relations.

“We are incredibly proud to receive this recognition, which underscores our commitment to innovation and investment in the Netherlands. This achievement would not have been possible without the dedication of our talented team and the support of our partners,” said Ziryan Othman.

Congratulations to the entire NBIL team for this outstanding accomplishment!

About Nikon BioImaging Lab Europe (NBIL):

NBIL is a Contract Research Organization (CRO) that provides microscope-basedimaging and analysis services to the biotech, pharma, and larger research communities.

About the Deshima Awards:

The Deshima Awards, established in 2007 by NFIA and DUJAT, honour Japanese companies making significant contributions to the Dutch economy, reflecting the deep-rooted economic ties between Japan and the Netherlands.

Press Contact:

Natalia Alexander

Nikon Europe B.V.

marketing.healthcare.eu@nikon.com


  • Sharp rise in venture capital at Leiden Bio Science Park

    Companies at Leiden Bio Science Park attracted around €350 million in venture capital in 2025. That is significantly more than in previous years. This is according to research by real estate advisor CBRE. Venture capital is money invested in new…

  • Permit application submitted for production facility

    On 3 April 2026, RED Company submitted the permit application for the construction of Lilly’s production facility to the Municipality of Katwijk. To demonstrate that the development is feasible and complies with all applicable laws and regulations, RED Company has…

  • Large study reveals hidden potential of cancer drugs

    Patients with advanced cancer for whom standard treatments no longer work may benefit from off-label medicines: approved drugs that are used for a different disease than the one for which they are officially registered. This means a larger group of…